Cimeitidine Tablet 200mg GMP Certificated

Product Details
Customization: Available
Price: Low Price
Export Country: Africa
Still deciding? Get samples of US$ 0.01/pcs
Request Sample
Manufacturer/Factory & Trading Company
Gold Member Since 2019

Suppliers with verified business licenses

Audited Supplier

Audited by an independent third-party inspection agency

Number of Employees
150
Year of Establishment
2004-01-16
  • Cimeitidine Tablet 200mg GMP Certificated
  • Cimeitidine Tablet 200mg GMP Certificated
  • Cimeitidine Tablet 200mg GMP Certificated
  • Cimeitidine Tablet 200mg GMP Certificated
  • Cimeitidine Tablet 200mg GMP Certificated
  • Cimeitidine Tablet 200mg GMP Certificated
Find Similar Products

Basic Info.

Model NO.
200mg 400mg
Specifications
200mg 400mg
Transport Package
Carton
Specification
200mg 400mg
Trademark
OEM
Origin
China
HS Code
3004909099
Production Capacity
5000000box

Product Description


Cimeitidine Tablet 200mg GMP CertificatedIndications:
For the treatment of duodenal ulcer, gastric ulcer, reflux esophagitis, stress ulcer and Zollinger-Ellison syndrome.
Adverse reactions
The adverse reactions of this product are generally uncommon and usually disappear after continued use or after withdrawal.
  1. The more common adverse reactions are diarrhea, fatigue, dizziness, lethargy, headache and rash.
  2. This product has a mild anti-androgenic effect. When the dosage is large (1.6g or more per day), it can cause male breast development, female galactorrhea, loss of libido, impotence, reduction of sperm count, etc., disappear after stopping the drug.
3. This product can pass the blood-cerebrospinal fluid barrier and has certain neurotoxicity. Occasionally, mental disorders, anxiety, depression, anxiety, paralysis, hallucinations, and disorientation are more common in elderly and seriously ill patients. Symptoms disappear after 3-4 days after stopping the drug. In the treatment of gastrointestinal comorbidities in alcoholics, tremors may occur, similar to alcohol withdrawal syndrome;
4. The rare adverse reactions of this product are: allergic reaction, fever, joint pain, myalgia, interstitial nephritis, urinary retention, liver toxicity, pancreatitis.
5. Very few have leukopenia and agranulocytosis, and these people have other serious conditions, receiving drugs and treatments known to reduce blood cells. Thrombocytopenia and aplastic anemia are rarely reported. Occasionally, plasma creatinine or serum aminotransferase increased. Very rare hepatitis.
6. The use of H2 blockers is rare for bradycardia, tachycardia and heart block, as well as allergic vasculitis. All of these reactions usually disappear after stopping the drug.
Attention
1. For cancerous ulcers, a diagnosis should be made before use to avoid delay in treatment.
  2. In elderly patients, due to renal dysfunction, the reduction of the removal of this product can slow down, which can lead to an increase in blood drug concentration, so it is more prone to toxic reactions and symptoms such as dizziness and paralysis.
3. If you have a history of drug allergy, please follow the doctor's advice.
4. Diagnostic interference: False positive in gastric occult blood test within 15 minutes after oral administration; blood salicylic acid concentration, serum creatinine, prolactin, aminotransferase and other concentrations may increase; parathyroid hormone concentration may decrease.
5. In order to avoid nephrotoxicity, renal function should be checked during medication.
6. This product has a certain inhibitory effect on the bone marrow, and should pay attention to check the blood picture during the medication.
7. The neurotoxic symptoms of this product are very similar to those of central anticholinergic drugs. The treatment with cholinergic physostigmine can improve symptoms. Therefore, this product should be avoided at the same time as the central anticholinergic drugs to prevent aggravation of central nervous system toxicity.
8. In elderly patients, patients with chronic lung disease, diabetes, and immunodeficiency, the risk of community-acquired pneumonia may increase with H2-receptor antagonists. A large epidemiological study showed an increased risk of community-acquired pneumonia compared to patients receiving H2-receptor antagonists.
  9. The following situations should be used with caution:
(1) Severe heart and respiratory disorders.
(2) In patients with systemic lupus erythematosus (SLE), the bone marrow toxicity of cimetidine may increase.
(3) organic encephalopathy.
(4) liver and kidney dysfunction.
10. Keep this medicine out of the reach of children.
Specification:
1x10's/box; 1x20's/box
Usage and dosage:
Oral, as directed by your doctor
for Export use only
Cimeitidine Tablet 200mg GMP CertificatedCimeitidine Tablet 200mg GMP CertificatedCimeitidine Tablet 200mg GMP Certificated

Send your message to this supplier

*From:
*To:
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now
Contact Supplier